Tracer library / [177Lu]Lu-PSMA-617-treated

[177Lu]Lu-PSMA-617-treated

Also written as Lu-177-PSMA-617-treated; [Lu-177]Lu-PSMA-617-treated

Radionuclide: Lu-177 t½ 9584.6 min
Modality: Therapy
Production route: —
Stage: Clinical research
Syntheses indexed: 0

Prostate cancer Preclinical only, no clinical indication yet PSMA-directed radioligand therapy

What it is

Compound class: PSMA-targeted radioligand therapy (small-molecule, urea-based agent labeled with lutetium-177)
Target / mechanism: Prostate-specific membrane antigen (PSMA) PMID 33840558
Clinical application: Metastatic castration-resistant prostate cancer (mCRPC) PMID 33840558
Theranostic pair: —

Published syntheses

No synthesis has been parsed for this agent yet.

Clinical literature

Clinical studies in the indexed corpus, ordered by design (multicentre, prospective, retrospective, others, case reports last) and then by year. Titles and links only, as published; this is not a summary of the evidence.

Evaluation of [68Ga]Ga-PSMA PET/CT for therapy response assessment of [177Lu]Lu-PSMA radioligand therapy in metastasized castration refractory prostate cancer and correlation with survival.
2021 · Nucl Med Commun · Retrospective

Need this precursor?We can point you to suppliers for [177Lu]Lu-PSMA-617-treated, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 4 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. | Stage 30 (2026-09-18): Stage was 'investigational'; normalised to 'Clinical research', original wording kept here.